Genexine, Inc. (KOSDAQ:095700)
South Korea · Delayed Price · Currency is KRW 3,010.00
+365.00 (13.80%)
Sep 1, 2026, 3:30 PM KST
Genexine Market Cap
Genexine has a market cap or net worth of 136.89 billion as of September 1, 2026. Its market cap has decreased by -41.67% in one year.
Market Cap
136.89B
Enterprise Value
n/a
Revenue
5.81B
Ranking
n/a
PE Ratio
n/a
Stock Price
3,010.00
ChartMarket Cap Chart
Since September 15, 2009, Genexine's market cap has increased from 109.02B to 136.89B, an increase of 25.57%. That is a compound annual growth rate of 1.35%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 1, 2026 | 136.89B | -35.75% |
| Dec 30, 2025 | 213.07B | -12.27% |
| Dec 30, 2024 | 242.86B | -40.82% |
| Dec 28, 2023 | 410.35B | -12.73% |
| Dec 29, 2022 | 470.21B | -67.78% |
| Dec 30, 2021 | 1.46T | -52.47% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| GC Cell | 202.87B |
| HLB Therapeutics | 196.24B |
| Anterogen.Co.,Ltd. | 151.39B |
| Helixmith | 142.75B |
| GC Genome | 141.20B |
| MedPacto | 95.46B |
| Vaxcell-Bio Therapeutics | 93.15B |
| iNtRON Biotechnology | 86.50B |